The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats

被引:6
|
作者
Zarif, A
Eiznhamer, D
Callaghan, C
Doria, MI
Broutman, L
Keshavarzian, A
机构
[1] LOYOLA UNIV,MED CTR,DIV DIGEST DIS & NUTR,SCH MED,DEPT MED,MAYWOOD,IL 60153
[2] LOYOLA UNIV,SCH MED,DEPT PHARMACOL,MAYWOOD,IL 60153
[3] LOYOLA UNIV,SCH MED,DEPT PATHOL,MAYWOOD,IL 60153
[4] ABBOTT LABS,ABBOTT PK,IL 60064
[5] HINES VIRGINIA,MED SERV,HINES,IL
[6] HINES VIRGINIA,RES SERV,HINES,IL
关键词
D O I
10.1007/BF01488200
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Though the mechanism of tissue damage induced by colonic inflammation in ulcerative colitis is unknown, it has been established that the inflammatory mediator and potent neutrophil (PMN) chemotaxin, leukotriene B4(LTB(4)), is present in elevated amounts in the inflamed mucosa. The unique role of 5-lipoxygenase in the production of leukotrienes has made it a target for inhibition. This study used a rat model of acute colonic inflammation induced by a single IP injection of Mitomycin-C to test the efficacy of a specific and potent 5-lipoxygenase inhibitor zileuton in the treatment of colonic inflammation. We hypothesized that after inducing colitis in rats with mitomycin-C, the administration of oral zileuton would inhibit leukotriene production, thus preventing PMN infiltration and subsequent tissue damage. Zileuton decreased colonic tissue damage as measured by Histological score. However, zileuton did not significantly decrease neutrophil infiltration measured by mucosal PMN or myeloperoxidase (MPO) levels. Although zileuton was successful in significantly decreasing the frequency of severe colitis in our model, the fact that the decrease in PMN count and MPO Level was not statistically significant suggests that another mechanism may be involved in its anti-inflammatory effect.
引用
收藏
页码:217 / 227
页数:11
相关论文
共 50 条
  • [1] SYNTHESIS OF CHIRAL ZILEUTON, A POTENT AND SELECTIVE INHIBITOR OF 5-LIPOXYGENASE
    HSIAO, CN
    KOLASA, T
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1992, 203 : 442 - ORGN
  • [2] SYNTHESIS OF CHIRAL ZILEUTON, A POTENT AND SELECTIVE INHIBITOR OF 5-LIPOXYGENASE
    HSIAO, CN
    KOLASA, T
    TETRAHEDRON LETTERS, 1992, 33 (19) : 2629 - 2632
  • [3] Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats
    Singh, VP
    Patil, CS
    Kulkarni, SK
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2005, 81 (03) : 433 - 439
  • [4] ZILEUTON - A 5-LIPOXYGENASE INHIBITOR IN RHEUMATOID-ARTHRITIS
    WEINBLATT, ME
    KREMER, JM
    COBLYN, JS
    HELFGOTT, S
    MAIER, AL
    PETRILLO, G
    HENSON, B
    RUBIN, P
    SPERLING, R
    JOURNAL OF RHEUMATOLOGY, 1992, 19 (10) : 1537 - 1541
  • [6] Zileuton: The first 5-lipoxygenase inhibitor for the treatment of asthma
    Wenzel, SE
    Kamada, AK
    ANNALS OF PHARMACOTHERAPY, 1996, 30 (7-8) : 858 - 864
  • [7] SYNTHESIS OF THE 5-LIPOXYGENASE INHIBITOR ZILEUTON FROM THIOPHENOL
    BASHA, A
    BROOKS, DW
    JOURNAL OF ORGANIC CHEMISTRY, 1993, 58 (05): : 1293 - 1294
  • [8] KINETICS AND MECHANISM OF DEGRADATION OF ZILEUTON, A POTENT 5-LIPOXYGENASE INHIBITOR
    ALVAREZ, FJ
    SLADE, RT
    PHARMACEUTICAL RESEARCH, 1992, 9 (11) : 1465 - 1473
  • [9] EFFECTS OF ZILEUTON, A NEW 5-LIPOXYGENASE INHIBITOR, IN EXPERIMENTALLY-INDUCED COLITIS IN RATS
    ZINGARELLI, B
    SQUADRITO, F
    GRAZIANI, P
    CAMERINI, R
    CAPUTI, AP
    AGENTS AND ACTIONS, 1993, 39 (3-4): : 150 - 156
  • [10] THE DISCOVERY AND DEVELOPMENT OF ZILEUTON - AN ORALLY ACTIVE 5-LIPOXYGENASE INHIBITOR
    BELL, RL
    YOUNG, PR
    ALBERT, D
    LANNI, C
    SUMMERS, JB
    BROOKS, DW
    RUBIN, P
    CARTER, GW
    INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1992, 14 (03): : 505 - 510